Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...